Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

652
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
652
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

4.0K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.0K
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: SIRT7 activates p53 by enhancing PCAF-mediated MDM2 degradation to arrest the cell cycle.

Oncogene·2026
Same author

Alexithymia of nursing students in higher vocational college: application of latent profile analysis and network analysis.

Frontiers in psychiatry·2026
Same author

Machine learning-based retrieval of total nitrogen matter from an inland highly turbid lake using Landsat 8 OLI Imagery.

Environmental monitoring and assessment·2026
Same author

Spectral CT quantification of organ mass and physical density: A non-invasive metric for assessing functional reserve in type 2 diabetes.

The International journal of artificial organs·2026
Same author

Eco-Friendly Low-Cost Design of Superhydrophobic Cu Mesh for Efficient Oil-Water Separation.

Molecules (Basel, Switzerland)·2026
Same author

Differentiation of arterioles and capillaries in human blood vessel organoids with decellularized splenic matrix.

Bioactive materials·2026

Related Experiment Video

Updated: Jun 26, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K

Individualized Dose-Response to Statins Associated with Cardiovascular Disease Outcomes.

Sachin K Aggarwal1, Lan Jiang2, Ge Liu2

  • 1Vanderbilt University School of Medicine, Nashville, TN, USA.

JACC. Advances
|May 13, 2024
PubMed
Summary

Statin potency (ED50) and efficacy (Emax) are linked to cardiovascular outcomes. Understanding these dose-response parameters can help personalize statin therapy for atherosclerotic cardiovascular disease (ASCVD) prevention.

Keywords:
cardiovascular outcomesdose responsepharmacodynamicsprecision medicinestatin

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.3K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.3K

Related Experiment Videos

Last Updated: Jun 26, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.3K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.3K

Area of Science:

  • Pharmacology
  • Cardiology
  • Data Science

Background:

  • Statins effectively lower low-density lipoprotein cholesterol (LDL-C) and prevent atherosclerotic cardiovascular disease (ASCVD).
  • Individual patient responses to statins vary, influenced by baseline LDL-C (E0), potency (ED50), and maximum efficacy (Emax).
  • The relationship between individualized statin dose-response parameters and ASCVD event risk remains unclear.

Purpose of the Study:

  • To analyze the association between statin potency (ED50) and efficacy (Emax) with real-world cardiovascular disease outcomes.
  • To investigate how individualized pharmacological properties of statins relate to ASCVD events and all-cause mortality.

Main Methods:

  • Utilized de-identified electronic health records from individuals prescribed atorvastatin, simvastatin, or rosuvastatin.
  • Derived ED50 and Emax using a nonlinear, mixed effects dose-response model for 3,033 patients.
  • Performed time-to-event analyses to assess the relationship between ED50, Emax, and a composite endpoint of ASCVD events and all-cause mortality.

Main Results:

  • Estimated ED50 and Emax for atorvastatin, simvastatin, and rosuvastatin cohorts.
  • Found that ED50 and Emax were independently associated with the primary endpoint across statin types.
  • Reported significant hazard ratios for ED50 and Emax, indicating their influence on ASCVD risk.

Conclusions:

  • The study demonstrates a class-wide association between statin ED50 and Emax with clinical outcomes.
  • These pharmacological parameters are significant predictors of ASCVD event risk in patients receiving statin therapy.
  • Individualized dose-response metrics can inform risk stratification and personalize statin treatment strategies.